Scinopharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 10, 2021
Share
ScinoPharm Taiwan, Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 747.638 million compared to TWD 908.080 million a year ago. Operating income was TWD 110.772 million compared to TWD 207.767 million a year ago. Net income was TWD 90.699 million compared to TWD 162.099 million a year ago. Basic earnings per share was TWD 0.11 compared to TWD 0.2 a year ago. For the half year, sales was TWD 1,388.774 million compared to TWD 1,450.603 million a year ago. Operating income was TWD 221.125 million compared to TWD 252.425 million a year ago. Net income was TWD 180.937 million compared to TWD 197.455 million a year ago. Basic earnings per share was TWD 0.23 compared to TWD 0.25 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
